Real-World Experience of Guselkumab in the Elderly Population
Guselkumab is effective and well tolerated in older adults with psoriasis. Baseline ELR, early PASI response, and chronic use of beta-blockers or aspirin may influence long-term treatment outcomes. While limited by the small sample size (66 patients), our findings represent the longest real-world follow-up to date among older psoriatic patients treated with guselkumab and support its use as a valuable therapeutic option in this population.
Authors
- Enrico Zelin (ORCID: https://orcid.org/0000-0001-9276-3627)
- Vanessa Mazzoletti (ORCID: https://orcid.org/0009-0000-0875-4948)
- Enzo Errichetti (ORCID: https://orcid.org/0000-0002-7152-6136)
- Zeno Fratton (ORCID: https://orcid.org/0000-0002-7454-1999)
- Vincenzo Maione (ORCID: https://orcid.org/0000-0002-0420-5009)
- Stefano Bighetti (ORCID: https://orcid.org/0009-0006-2781-6909)
- Giuseppe Stinco (ORCID: https://orcid.org/0000-0002-2392-9504)
- Luca Bettolini (ORCID: https://orcid.org/0000-0003-4374-802X)
- M. Venturini
- Mariateresa Rossi
Institutions
- University of Udine (IT)
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT)
- Ospedale Santa Maria della Misericordia di Udine (IT)
- University of Brescia (IT)
Publication Details
- Journal
- Psoriasis Targets and Therapy
- Published
- 2025-12-01
- DOI
- https://doi.org/10.2147/ptt.s549502
- Citations
- 1
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.80